Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

7.005 +0.255 (+3.78%)
Streaming Delayed Price Updated: 11:37 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗
Via Stocktwits
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
The company has solid potential with its development of drugs targeting muscle disorders. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗
BioCryst (BCRX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗
Via Stocktwits
BioCryst To Acquire Astria Therapeutics In $700M Deal ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For BioCryst Pharma ↗
 
Via Benzinga
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
Via Benzinga
News headline image
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗
BioCryst Q3 2025 results: Earnings beat estimates with $0.06 EPS, but revenue of $159.4M missed forecasts. ORLADEYO sales grew 37%. 
Via Chartmill
Topics Earnings
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' ↗
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth. 
Via Benzinga
News headline image
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level ↗
CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth ↗
BioCryst Pharmaceuticals (BCRX) beats Q2 2025 estimates with strong revenue and profit growth, driven by ORLADEYO sales. Shares rise ~5% pre-market. 
Via Chartmill
News headline image
BioCryst (BCRX) Q2 Revenue Jumps 50% ↗
Via The Motley Fool
News headline image
BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering ↗
BioCryst sells European Orladeyo rights to Neopharmed for up to $264 million, plans to eliminate term debt and boost long-term cash position. 
Via Benzinga
News headline image
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish ↗
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up... 
Via Stocktwits
News headline image
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
BIOCRYST PHARMACEUTICALS (NASDAQ:BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
News headline image
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
BIOCRYST PHARMACEUTICALS (BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors. 
Via Chartmill
News headline image
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish ↗
BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year. 
Via Stocktwits
News headline image
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors ↗
BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow. 
Via Benzinga
News headline image
Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.